RARE (Ultragenyx Pharmaceutical) Cash Flow from Operations : $-389.9 Mil (TTM As of Mar. 2025)

Ultragenyx Pharmaceutical Cash Flow from Operations Chart

Ultragenyx Pharmaceutical Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Cash Flow from Operations		Get a 7-Day Free Trial					-132.22	-338.70	-380.47	-474.81	-414.19

Ultragenyx Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash Flow from Operations	Get a 7-Day Free Trial															-190.73	-76.96	-67.00	-79.50	-166.48

Ultragenyx Pharmaceutical Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Ultragenyx Pharmaceutical's Cash Flow from Operations for the fiscal year that ended in Dec. 2024 is calculated as:

Ultragenyx Pharmaceutical's Cash Flow from Operations for the quarter that ended in Mar. 2025 is:

Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-389.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical  (NAS:RARE) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Ultragenyx Pharmaceutical's net income from continuing operations for the three months ended in Mar. 2025 was $-151.1 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Ultragenyx Pharmaceutical's depreciation, depletion and amortization for the three months ended in Mar. 2025 was $9.0 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Ultragenyx Pharmaceutical's change in working capital for the three months ended in Mar. 2025 was $-56.6 Mil. It means Ultragenyx Pharmaceutical's working capital declined by $56.6 Mil from Dec. 2024 to Mar. 2025 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Ultragenyx Pharmaceutical's cash flow from deferred tax for the three months ended in Mar. 2025 was $0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Ultragenyx Pharmaceutical's cash from discontinued operating Activities for the three months ended in Mar. 2025 was $0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Ultragenyx Pharmaceutical's asset impairment charge for the three months ended in Mar. 2025 was $0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Ultragenyx Pharmaceutical's stock based compensation for the three months ended in Mar. 2025 was $39.9 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Ultragenyx Pharmaceutical's cash flow from others for the three months ended in Mar. 2025 was $-7.7 Mil.

Ultragenyx Pharmaceutical Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical Business Description